Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ORIC

ORIC Pharmaceuticals Inc

Oct 24 • 04:00PM ET

13.10

+0.68 5.48 %

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRK BMY GILD ABBV AMGN LLY VRTX REGN BIIB

| Held by: VTI IWM XBI VXF IWN SCHA IBB VTWO FESM IWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.89	Insider Own	42.25%	Shs Outstand	86.19M	Perf Week	2.50%
Market Cap	1.27B	Forward P/E	-	EPS next Y	-1.70	Insider Trans	-0.71%	Shs Float	56.09M	Perf Month	25.84%
Enterprise Value	993.07M	PEG	-	EPS next Q	-0.41	Inst Own	62.05%	Short Float	23.21%	Perf Quarter	17.17%
Income	-137.25M	P/S	-	EPS this Y	5.65%	Inst Trans	7.41%	Short Ratio	9.69	Perf Half Y	156.86%
Sales	0.00M	P/B	3.48	EPS next Y	1.42%	ROA	-40.62%	Short Interest	13.02M	Perf YTD	62.33%
Book/sh	3.76	P/C	4.50	EPS next 5Y	4.34%	ROE	-43.82%	52W High	14.93 -12.26%	Perf Year	50.40%
Cash/sh	2.91	P/FCF	-	EPS past 3/5Y	4.02% -15.32%	ROIC	-42.36%	52W Low	3.90 236.32%	Perf 3Y	362.90%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	6.01% 6.64%	Perf 5Y	-46.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-7.33%	Oper. Margin	-	ATR (14)	0.78	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	16.13	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	55.86	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	16.13	EPS Q/Q	-2.40%	SMA20	1.39%	Beta	1.65	Target Price	18.27
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	14.98%	Rel Volume	1.09	Prev Close	12.42
Employees	115	LT Debt/Eq	0.00	Earnings	Aug 12 AMC	SMA200	44.38%	Avg Volume	1.34M	Price	13.10
IPO	Apr 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.09% -	Trades		Volume	1,462,938	Change	5.48%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-25	Resumed	Guggenheim	Buy	$18
Jul-08-25	Initiated	Ladenburg Thalmann	Buy	$15
Oct-31-24	Initiated	Wells Fargo	Overweight	$20
Sep-06-24	Initiated	Stifel	Buy	$20
Feb-23-24	Initiated	Cantor Fitzgerald	Overweight
Sep-22-23	Initiated	Wedbush	Outperform	$8
Mar-23-23	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Mar-21-23	Upgrade	Guggenheim	Neutral → Buy	$15
Mar-16-23	Upgrade	Oppenheimer	Perform → Outperform	$14
Jul-18-22	Resumed	Oppenheimer	Perform
Apr-04-22	Upgrade	Citigroup	Neutral → Buy	$7 → $10
Mar-25-22	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-22-22	Downgrade	Oppenheimer	Outperform → Perform
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Mar-22-22	Downgrade	Citigroup	Buy → Neutral	$22 → $7
Jul-06-21	Upgrade	Citigroup	Neutral → Buy	$34
Jan-25-21	Downgrade	Citigroup	Buy → Neutral	$34
Aug-13-20	Initiated	Robert W. Baird	Outperform	$45
Aug-06-20	Upgrade	Citigroup	Neutral → Buy	$35
Aug-03-20	Initiated	H.C. Wainwright	Buy	$52

Show Previous Ratings

Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks)
Sep-17-25 01:45PM	Oric Pharmaceuticals Stock Scores RS Rating Upgrade (Investor's Business Daily)
Sep-05-25 04:05PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-27-25 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-18-25 04:05PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer (GlobeNewswire)
04:05PM	Loading…
Aug-12-25 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Updates (GlobeNewswire)
Aug-01-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-15-25 09:55AM	Oric Pharmaceuticals, Inc. (ORIC) Now Trades Above Golden Cross: Time to Buy? (Zacks)
Jul-11-25 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) is a Great Momentum Stock: Should You Buy? (Zacks)
Jul-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-19-25 12:00PM	All You Need to Know About Oric Pharmaceuticals (ORIC) Rating Upgrade to Buy (Zacks)
09:55AM	Does Oric Pharmaceuticals (ORIC) Have the Potential to Rally 104.99% as Wall Street Analysts Expect? (Zacks)
Jun-13-25 12:00PM	What Makes Oric Pharmaceuticals, Inc. (ORIC) a Strong Momentum Stock: Buy Now? (Zacks)
11:30AM	JPMorgan biotech/pharma analysts hold analyst/industry conference call (TipRanks)
Jun-06-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79%
09:55AM	Loading…
Jun-02-25 09:55AM	Wall Street Analysts Predict a 131.33% Upside in Oric Pharmaceuticals (ORIC): Here's What You Should Know (Zacks)
May-29-25 11:53AM	ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study (Zacks) +33.50%
12:09AM	ORIC Pharmaceuticals, Inc. (ORIC) Secures $125M to Advance ORIC-944 Phase 3 Trials (Insider Monkey)
May-28-25 04:05PM	ORIC Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC (GlobeNewswire)
04:05PM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
May-27-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -8.98%
08:00AM	ORIC Pharmaceuticals to Present Initial Data from Phase 1b Trial of ORIC-944 in Combination with Androgen Receptor Inhibitors in Patients with mCRPC (GlobeNewswire)
May-05-25 04:05PM	ORIC Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates (GlobeNewswire) -11.58%
May-02-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 04:30PM	ORIC Pharmaceuticals Presents Preclinical Data to Support the Potential of ORIC-944 as a Best-in-Class PRC2 Inhibitor for the Treatment of Prostate Cancer at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +11.10%
Apr-22-25 09:15AM	ORIC Pharmaceuticals: Multiple Data Releases In 2025 Make It A Must-Watch Biotech (Seeking Alpha) +7.19%
07:30AM	ORIC Pharmaceuticals: Looking To The Horizon With Pivotal Study Plans (Seeking Alpha)
Apr-16-25 11:09AM	Is ORIC Pharmaceuticals Inc. (NASDAQ:ORIC) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -6.94%
Apr-04-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.22% -5.94%
Mar-31-25 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -9.12%
04:30PM	Loading…
Mar-25-25 04:30PM	ORIC Pharmaceuticals Announces ORIC-944 Preclinical Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -8.41% -13.33%
Mar-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-25-25 04:15PM	ORIC Pharmaceuticals Announces Focused Registrational Clinical Development Plans for Lead Programs, Extended Cash Runway, and Updated Corporate Milestones (GlobeNewswire) +6.88%
Feb-18-25 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -6.10%
Feb-07-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
Jan-27-25 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +7.85%
Jan-15-25 10:10AM	Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year (PR Newswire) +9.69%
Jan-14-25 08:35AM	Oric Pharmaceuticals announces clinical supply agreement with Janssen (TipRanks) +15.23%
Jan-13-25 08:05AM	ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones (GlobeNewswire) +8.04%
08:00AM	ORIC Pharmaceuticals Announces Clinical Supply Agreement to Evaluate ORIC-114 in Combination with Amivantamab for the First-Line Treatment of NSCLC with EGFR Exon 20 Insertion Mutations (GlobeNewswire)
Jan-06-25 04:15PM	ORIC Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.82%
Jan-03-25 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-25-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-12-24 04:05PM	ORIC Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
Nov-04-24 04:15PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-23-24 07:00AM	ORIC Pharmaceuticals Presents Data Further Supporting Potential Best-In-Class Profile of ORIC-114 to Treat EGFR Exon 20 Insertions and Other Atypical Mutations at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-09-24 04:15PM	ORIC Pharmaceuticals Announces Presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-04-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-17-24 12:00PM	OpenBench and ORIC Pharmaceuticals Launch Success-Driven Discovery Collaboration (PR Newswire)
Sep-14-24 05:35PM	ORIC Pharmaceuticals, Inc. (ORIC): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Sep-06-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-26-24 04:05PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +6.04%
Aug-12-24 04:05PM	ORIC Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Updates (GlobeNewswire) +6.76%
Aug-05-24 04:15PM	ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Keith Lui as Senior Vice President of Commercial and Medical Affairs (GlobeNewswire) -8.65%
Aug-02-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.48%
Jul-17-24 11:20AM	ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ (Zacks) -7.01%
Jul-16-24 04:59PM	ORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate Cancer (GlobeNewswire)
Jul-09-24 07:30AM	Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors (GlobeNewswire) +9.88%
Jul-08-24 06:00PM	Why Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts? (Insider Monkey) +10.53%
12:30PM	10 Most Shorted Stocks That Are Loved by Analysts (Insider Monkey)
Jul-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-07-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-29-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.68%
May-06-24 09:54PM	ORIC Stock Earnings: ORIC Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates (GlobeNewswire)
May-03-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-15-24 04:15PM	ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC (GlobeNewswire)
Apr-08-24 08:00AM	ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-05-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-04-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-26-24 09:55AM	How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3% (Zacks)
Mar-12-24 09:01PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results (GuruFocus.com) +6.35%
Mar-11-24 04:05PM	ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Mar-08-24 05:01PM	ORIC Pharmaceuticals Inc CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com) -5.78%
Mar-06-24 04:30PM	ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Mar-05-24 04:30PM	ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-01-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +15.07%
Feb-14-24 04:30PM	ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-09-24 02:23AM	ORIC Pharmaceuticals CEO Jacob Chacko Sells 40,000 Shares (GuruFocus.com)
Feb-08-24 08:50AM	Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why (Zacks)
Feb-02-24 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-01-24 03:05PM	Andreas Halvorsen's Viking Global Investors LP Acquires New Stake in ORIC Pharmaceuticals Inc (GuruFocus.com)
Jan-31-24 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Jan-23-24 08:50AM	Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Jan-22-24 08:30AM	ORIC Pharmaceuticals Announces $125 Million Private Placement Financing (GlobeNewswire)
Jan-09-24 12:31PM	Final Boarding Call: 3 Stocks Set for a Sky-High Surge (InvestorPlace)
Jan-08-24 08:30AM	ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones (GlobeNewswire)
Jan-02-24 04:30PM	ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-23 12:00PM	Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development (GlobeNewswire) -5.30%
Dec-05-23 09:11AM	3 Stocks at the Forefront of Personalized Medicine Trend (InvestorPlace)
Dec-01-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-09-23 04:30PM	ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.44%
Nov-06-23 05:22PM	ORIC Pharmaceuticals Inc (ORIC) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com)
04:10PM	ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates (GlobeNewswire)
Nov-03-23 04:30PM	ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-02-23 09:00AM	ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Oct-21-23 07:30AM	Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile (GlobeNewswire)
Oct-17-23 04:30PM	ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023 (GlobeNewswire)
Oct-16-23 12:00PM	Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Option Exercise	4.36	11,000	47,960	59,317	Oct 08 05:37 PM
Piscitelli Dominic	Chief Financial Officer	Oct 06 '25	Sale	14.52	11,000	159,719	48,317	Oct 08 05:37 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 06 '25	Sale	12.32	37,461	461,520	531,419	Oct 08 05:35 PM
Dominic Piscitelli	Officer	Oct 06 '25	Proposed Sale	14.50	50,000	725,000		Oct 06 04:22 PM
Heyman Richard A.	Director	Oct 03 '25	Option Exercise	1.69	32,800	55,591	45,300	Oct 03 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Oct 01 '25	Sale	12.05	53,001	638,805	568,880	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 30 '25	Sale	12.01	34,538	414,750	621,881	Oct 02 07:18 PM
Chacko Jacob	PRESIDENT AND CEO	Sep 22 '25	Sale	10.80	125,000	1,349,938	656,419	Sep 24 04:30 PM
Jacob Chacko	Director	Sep 22 '25	Proposed Sale	10.50	250,000	2,625,000		Sep 22 04:31 PM
Piscitelli Dominic	Chief Financial Officer	Jul 01 '25	Sale	10.05	20,000	200,972	48,317	Jul 02 04:07 PM
Piscitelli Dominic	Chief Financial Officer	Jun 24 '25	Sale	10.50	32,466	341,039	68,317	Jun 24 06:33 PM
Piscitelli Dominic	Chief Financial Officer	Jun 23 '25	Sale	10.00	1,034	10,344	100,783	Jun 24 06:33 PM
You Angie	Director	Jun 20 '25	Buy	9.39	26,597	249,669	26,597	Jun 23 08:05 PM
You Angie	Director	Jun 23 '25	Buy	9.43	1,403	13,230	28,000	Jun 23 08:05 PM
Piscitelli Dominic	Chief Financial Officer	Jun 12 '25	Sale	10.00	300	3,000	101,817	Jun 13 07:38 PM
Piscitelli Dominic	Chief Financial Officer	Jun 11 '25	Sale	10.01	2,976	29,777	102,117	Jun 11 06:37 PM
Piscitelli Dominic	Chief Financial Officer	Jun 10 '25	Sale	10.00	324	3,240	105,093	Jun 11 06:37 PM
Piscitelli Dominic	Chief Financial Officer	Jun 06 '25	Sale	10.01	2,600	26,021	104,164	Jun 09 08:18 PM
Piscitelli Dominic	Chief Financial Officer	Jun 09 '25	Sale	10.00	300	3,000	103,864	Jun 09 08:18 PM
Dominic Piscitelli	Officer	Jun 06 '25	Proposed Sale	9.00	60,000	540,000		Jun 06 04:16 PM
Kunkel Lori Anne	Director	Mar 03 '25	Option Exercise	4.85	48,166	233,512	68,666	Mar 04 05:27 PM
Piscitelli Dominic	Chief Financial Officer	Dec 15 '24	Option Exercise	0.00	24,042	0	115,615	Dec 17 05:23 PM
Piscitelli Dominic	Chief Financial Officer	Dec 16 '24	Sale	8.28	8,851	73,298	106,764	Dec 17 05:23 PM
Multani Pratik S	Chief Medical Officer	Dec 15 '24	Option Exercise	0.00	24,042	0	55,615	Dec 17 05:22 PM
Multani Pratik S	Chief Medical Officer	Dec 16 '24	Sale	8.28	8,850	73,293	46,765	Dec 17 05:22 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 15 '24	Option Exercise	0.00	67,000	0	803,308	Dec 17 05:21 PM
Chacko Jacob	PRESIDENT AND CEO	Dec 16 '24	Sale	8.28	24,660	204,214	778,648	Dec 17 05:21 PM
Multani Pratik S	Officer	Dec 16 '24	Proposed Sale	8.28	8,850	73,294		Dec 16 09:34 PM
Chacko Jacob	Officer	Dec 16 '24	Proposed Sale	8.28	24,660	204,215		Dec 16 09:31 PM
Piscitelli Dominic	Officer	Dec 16 '24	Proposed Sale	8.28	8,851	73,298		Dec 16 09:29 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ORIC

ORIC Pharmaceuticals Inc

Upgrade your FINVIZ experience